Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. 1349.HK Stock
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Price Chart
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. 1349.HK Financial and Trading Overview
Contents
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Price Chart
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. 1349.HK Financial and Trading Overview
- Valuation Measures
- Trading Information
- Financial Highlights
- Profile of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.
- Q&A For Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Stock
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. stock price | 2.08 HKD |
Previous Close | 2.69 HKD |
Open | 2.71 HKD |
Bid | 2.74 HKD x 0 |
Ask | 2.76 HKD x 0 |
Day's Range | 2.7 - 2.78 HKD |
52 Week Range | 2.51 - 3.58 HKD |
Volume | 480K HKD |
Avg. Volume | 330.68K HKD |
Market Cap | 7.73B HKD |
Beta (5Y Monthly) | 0.417241 |
PE Ratio (TTM) | 18.266666 |
EPS (TTM) | 0.11 HKD |
Forward Dividend & Yield | 0.08 (3.00%) |
Ex-Dividend Date | June 5, 2023 |
1y Target Est | N/A |
1349.HK Valuation Measures
Enterprise Value | 1.77B HKD |
Trailing P/E | 18.266666 |
Forward P/E | 9.785714 |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 7.1566825 |
Price/Book (mrq) | 1.2443234 |
Enterprise Value/Revenue | 1.637 |
Enterprise Value/EBITDA | 10.842 |
Trading Information
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Stock Price History
Beta (5Y Monthly) | 0.417241 |
52-Week Change | -18.23% |
S&P500 52-Week Change | 20.43% |
52 Week High | 3.58 HKD |
52 Week Low | 2.51 HKD |
50-Day Moving Average | 3.03 HKD |
200-Day Moving Average | 3.07 HKD |
1349.HK Share Statistics
Avg. Volume (3 month) | 330.68K HKD |
Avg. Daily Volume (10-Days) | 341.9K HKD |
Shares Outstanding | 326M |
Float | 455.31M |
Short Ratio | N/A |
% Held by Insiders | 21.64% |
% Held by Institutions | 12.65% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0.07 |
Trailing Annual Dividend Yield | 2.60% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0.5483 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 13.14% |
Operating Margin (ttm) | 10.85% |
Gross Margin | 91.38% |
EBITDA Margin | 15.09% |
Management Effectiveness
Return on Assets (ttm) | 2.63% |
Return on Equity (ttm) | 6.34% |
Income Statement
Revenue (ttm) | 1.08B HKD |
Revenue Per Share (ttm) | 1.05 HKD |
Quarterly Revenue Growth (yoy) | 34.30% |
Gross Profit (ttm) | 947.1M HKD |
EBITDA | 162.98M HKD |
Net Income Avi to Common (ttm) | 141.86M HKD |
Diluted EPS (ttm) | 0.15 |
Quarterly Earnings Growth (yoy) | 78.40% |
Balance Sheet
Total Cash (mrq) | 1.08B HKD |
Total Cash Per Share (mrq) | 1.05 HKD |
Total Debt (mrq) | 122.25M HKD |
Total Debt/Equity (mrq) | 5.41 HKD |
Current Ratio (mrq) | 3.435 |
Book Value Per Share (mrq) | 2.202 |
Cash Flow Statement
Operating Cash Flow (ttm) | 22.22M HKD |
Levered Free Cash Flow (ttm) | -57416728 HKD |
Profile of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.
Country | Hong Kong |
State | N/A |
City | Shanghai |
Address | Zhangjiang Hi-Tech Park |
ZIP | 201210 |
Phone | 86 21 5895 3355 |
Website | https://www.fd-zj.com |
Industry | Drug Manufacturers-Specialty & Generic |
Sector(s) | Healthcare |
Full Time Employees | 910 |
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., together with its subsidiaries, researches, develops, manufactures, and sells bio-pharmaceutical products. It offers genetic engineering platform drugs, including CD30-DM1 antibody-drug conjugate (ADC), which is in Phase I clinical trials for tumors; Trop2-SN38 ADC that is in Phase I clinical trials for triple negative, breast, bladder, gastric, and other tumors; Trop2-BB05 ADC that is in pre-clinical studies for lung cancer and triple negative breast cancer; and HER2 ADC that has completed pre-clinical research for metastatic breast and gastric cancers. The company also provides photodynamic technical platform drugs, such as hemoporfin for port wine stain, which is in Phase IV clinical trial; and aminolevulinic acid, which is in Phase II clinical trials for cervical diseases infected by HPV and acne, as well as completed pre-clinical study for brain gliomas. In addition, it offers nano technical platform drugs, such as Nanoparticle Albumin-bound Paclitaxel that is in pre-clinical studies for tumors, as well as developing Doxorubicin liposome for tumors. Further, the company offers oral solid preparation technology, which includes obeticholic acid for hepatobiliary and autoimmune disease; timolol maleate cream that is in pre-clinical studies for infantile hemangioma; and FZJ-003 oral preparation, which is in Phase I clinical trials for rheumatoid arthritis, as well as in Phase II clinical trials for atopic dermatitis and ulcerative colitis. Additionally, it develops pharmaceutical and medical devices; medical diagnostic products and related services; and sells daily necessities, and clinical laboratory analysis instruments and software. It also engages in the technology development, transfer, consulting, and promotion activities; produces freeze-dried powder injections and APIs; and invests in overseas medical projects. The company was founded in 1996 and is based in Shanghai, the People's Republic of China.
Q&A For Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Stock
What is a current 1349.HK stock price?
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. 1349.HK stock price today per share is 2.08 HKD.
How to purchase Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. stock?
You can buy 1349.HK shares on the HKSE exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.?
The stock symbol or ticker of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. is 1349.HK.
Which industry does the Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. company belong to?
The Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. industry is Drug Manufacturers-Specialty & Generic.
How many shares does Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. have in circulation?
The max supply of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. shares is 3.01B.
What is Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Price to Earnings Ratio (PE Ratio)?
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. PE Ratio is 18.90909000 now.
What was Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. earnings per share over the trailing 12 months (TTM)?
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. EPS is 0.11 HKD over the trailing 12 months.
Which sector does the Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. company belong to?
The Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. sector is Healthcare.